A Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients With Low-Grade Serous Ovarian, Fallopian Tube, or Peritoneal Cancer. The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-Label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or
Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum.